BPC-157
Also known as: Bepecin, Body Protection Compound-157, Body Protective Compound‑157, BPC 157, BPC157, PL 14736, Stable Gastric Pentadecapeptide BPC-157
Source BPC-157 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
BPC-157 is a 15‑amino‑acid peptide derived from a fragment of human gastric mucosal protein. It is investigated for its regenerative, anti‑ulcer, and anti‑inflammatory properties in pre‑clinical models.
Mechanism of Action
Promotes angiogenesis, upregulates VEGF and nitric oxide pathways, modulates inflammatory cytokines, and enhances fibroblast migration for tissue repair.
Routes of Administration
Goals & Uses
- Anti‑inflammatory effectInflammationLow
- Muscle repair and recoveryMusculoskeletal RepairLow
- Angiogenesis promotionVascularLow
- Tendon and ligament healingMusculoskeletal RepairModerate
- Gastrointestinal ulcer repairGastrointestinalModerate
- Neuroprotection and Neural RepairNeurologyLow
- Accelerate soft‑tissue healingRegenerativeModerate
- Anti-inflammatory effectsInflammationLow
- Gastrointestinal healing and protectionGI CytoprotectionModerate
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- History of hormone-sensitive cancersOncologicalModerate
- Severe hepatic impairmentOrganLowLiver function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to BPC-157 or excipientsAllergyHigh
Adverse Effects
- Dizziness or lightheadednessNeurologicalUncommon
- Theoretical tumor promotionOncologicalUnknown
- Injection site reactionsLocalCommon
- Hormonal axis perturbationEndocrineUnknown
- Local injection site irritationLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- Dopaminergic agents (e.g., L-DOPA, dopamine agonists)Moderate
- VEGF-targeting therapies (e.g., bevacizumab)High
- Anticoagulants / antiplateletsModerate
- NSAIDsLowMay increase renal risk in susceptible patients
Population Constraints
- Pediatric patientsAgeAbsolute
- Elderly >75 yearsAgeRelative
- Patients with active cancerOncologicalRelative
- Pregnant or lactating womenReproductiveAbsolute
- Children <12 yearsAgeRelative
- Immunocompromised individualsImmunologicalRelative
Regulatory Status
- European UnionUnapprovedNo EMA marketing authorization; only for laboratory use.
- United StatesUnapprovedClassed as investigational research chemical; not FDA‑approved.
- United KingdomUnapprovedNot licensed by MHRA; restricted to research.
Not approved for human use in the US, EU, or UK; available only as a research chemical.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is BPC-157?
BPC-157 is a 15‑amino‑acid peptide derived from a fragment of human gastric mucosal protein. It is investigated for its regenerative, anti‑ulcer, and anti‑inflammatory properties in pre‑clinical models.
What is BPC-157 used for?
BPC-157 is educationally associated with: Anti‑inflammatory effect, Muscle repair and recovery, Angiogenesis promotion, Tendon and ligament healing, Gastrointestinal ulcer repair, Neuroprotection and Neural Repair, Accelerate soft‑tissue healing, Anti-inflammatory effects, Gastrointestinal healing and protection. Educational only — not medical advice.
How is BPC-157 administered?
Recorded routes of administration: Intramuscular, Intraperitoneal, Oral, Subcutaneous.
What are the potential side effects of BPC-157?
Reported adverse effects include: Dizziness or lightheadedness, Theoretical tumor promotion, Injection site reactions, Hormonal axis perturbation, Local injection site irritation, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid BPC-157?
Recorded contraindications: Active malignancy, History of hormone-sensitive cancers, Severe hepatic impairment, Pregnancy, Known hypersensitivity to BPC-157 or excipients. Consult a qualified clinician before use.